Vilazodone for the Treatment of Paternal Post Natal Depression
Hani Raoul Khouzam*
Medical Director, Employee Behavioral Health Dartmouth – Hitchcock Medical Center, Professor of Psychiatry, The Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA
- *Corresponding Author:
- Khouzam H
Employee Behavioral Health Dartmouth – Hitchcock Medical Center
Professor of Psychiatry
The Geisel School of Medicine at Dartmouth, Hanover
New Hampshire, USA
E-mail: [email protected]
Received Date: November 02, 2015; Accepted Date: November 03, 2015; Published Date: Novomber 15, 2015
Citation: Khouzam HR (2015) Vilazodone for the Treatment of Paternal Post Natal Depression. Clin Depress 1:104. doi:10.4172/2572-0791.1000104
Copyright: © 2015 Khouzam HR. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Maternal postpartum depression is well recognized by clinicians as one of the psychiatric complication of delivery, conversely paternal postpartum depression or paternal postnatal depression which affects up to 10% -14% of new fathers 6 to 12 months after a child birth is rarely recognized and treated. Without proper diagnosis and prompt treatment paternal postnatal depression could lead to dire consequences including, deterioration in paternal mental health, loss of paternal bonding with the newborn child, which has been associated with long term later child psychiatric complications such as conduct disorders, hyperactivity, anxiety, depression, posttraumatic stress disorder and delays in language acquisition. It can also lead to marital conflicts, stressful family interactions and psychiatric disability leading to potential loss of income, and increase medical care costs. Like major depressive disorders the treatment of paternal postnatal depression may require psychopharmacological treatment typically with selective serotonin reuptake inhibitors or serotonin norepinephrine reuptake inhibitors. The purpose of this report is to increase clinicians awareness in recognizing and treating paternal postnatal depression as illustrated in a case of a 30 year-old new father who developed paternal postnatal depression and his progress in response to treatment with the first-of-class serotonin partial agonist reuptake inhibitor antidepressant vilazodone which basic pharmacology is summarized.